Infliximab Biosimilar May Launch In October; J&J To Appeal Patent Ruling

The federal district court in Massachusetts dealt a setback to Janssen by agreeing with biosimilar makers Celltrion and Hospira that Janssen's '471 patent for the brand biologic Remicade is invalid. The biosimilar makers could launch their infliximab product in October, but Janssen parent company Johnson & Johnson said Wednesday (Aug. 17) such a move would be risky because J&J plans to appeal the ruling and continue seeking U.S. Patent & Trademark Office backing. J&J said it will continue to defend...